Xencor Stock Price, News & Analysis

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will present at the virtual 2023 SVB Securities Global Biopharma Conference on February 14, 2023, at 3:40 p.m. ET. The presentation will focus on the company's innovative engineered antibodies and cytokines aimed at treating cancer and autoimmune diseases. A live webcast will be available in the Investors section of Xencor's website, with an archived replay accessible for at least 30 days following the event. Xencor is advancing over 20 clinical candidates developed with its XmAb® technology.

Xencor, Inc. (NASDAQ:XNCR) has announced its 2023 corporate priorities and clinical updates in oncology and autoimmune diseases. The company is advancing several bispecific antibodies, including plamotamab and vudalimab, focusing on treating solid tumors and B-cell malignancies. Notably, XmAb564, targeting regulatory T cells, shows promise in autoimmune treatments. Xencor maintains a strong financial position with approximately $610 million in cash, projected to fund operations through 2025.

Caris Life Sciences and Xencor, Inc. have expanded their collaboration to research and develop novel XmAb bispecific antibodies aimed at treating cancer. This agreement builds on the initial partnership from August 2022 and will increase the number of targets and cancer types that Caris will investigate using its Caris Discovery platform. Xencor gains exclusive global rights to develop products from up to three discovered targets. Caris will receive an upfront payment and could earn up to $187 million in milestone payments, along with royalties on future sales.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will have its CEO Bassil Dahiyat present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 11, 2023, at 3:45 p.m. PST. A live webcast will be accessible in the Investors section of Xencor's website, with a replay available for 30 days post-event. Xencor focuses on developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 clinical candidates and three marketed medicines through partnerships.

Xencor, Inc. (NASDAQ: XNCR) announced new clinical data from its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody for relapsed or refractory non-Hodgkin lymphomas, presented at the ASH Annual Meeting. The data indicated a well-tolerated safety profile, with a 52% overall response rate in patients with DLBCL or HGBCL, and 88% in follicular lymphoma. Adverse events included neutropenia and cytokine release syndrome. Xencor aims to develop plamotamab in various chemotherapy-free regimens, indicating a strategic focus on improving treatment outcomes for B-cell cancers.

Xencor, a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol XNCR, announced participation in two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 15, 2022, at 8:00 a.m. GMT, followed by the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 12:30 p.m. EST. Live webcasts will be accessible via the company’s website, with replays available for 30 days post-event. Xencor specializes in engineered antibodies and cytokines for cancer and autoimmune disease treatments.

Xencor, Inc. (NASDAQ:XNCR) presented initial data from the Phase 2 study of vudalimab, a bispecific antibody, targeting metastatic castration-resistant prostate cancer (mCRPC) at the Society for Immunotherapy of Cancer Annual Meeting in Boston. The study included nine patients, with three showing more than 50% PSA reductions. However, safety concerns led to a reduction in chemotherapy intensity for future cohorts. Xencor plans to explore alternative chemotherapy combinations and has multiple ongoing studies for vudalimab and other XmAb programs.

Xencor, Inc. (NASDAQ:XNCR) reported Q3 2022 results, showing $27.3 million in revenue, up from $19.7 million in Q3 2021. The net loss decreased to $32.8 million or $(0.55) per share, compared to $(0.69) in Q3 2021. Key highlights include promising results from the XmAb564 IL-2 cytokine study, demonstrating a 117-fold Treg expansion. Xencor anticipates ending 2022 with $575 million to $600 million in cash and expects to fund R&D through 2025. Additional updates on clinical programs are forthcoming.

Xencor announced positive topline results from the Phase 1a study of XmAb564, a novel therapy targeting regulatory T cells (Tregs) for autoimmune diseases. A 117-fold increase in CD25^bright Tregs was observed at the highest dose, with sustained activity over three weeks. XmAb564 was well-tolerated, showing no serious adverse events, and the first patient has been dosed in a Phase 1b study for atopic dermatitis and psoriasis. Results will be discussed in a webcast today at 4:30 PM ET.